FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Human Drugs

AstraZeneca/Merck NDA for Neurofibromatosis Drug

FDA accepts for priority review an AstraZeneca and Merck NDA for MEK 1/2 inhibitor selumetinib for pediatric patients with neurofibromatosis type 1 an...

Human Drugs

ICH Q12 Guidance Extends Quality by Design: Analysis

CGMP consultant Dave Elder analyzes a draft International Conference on Harmonization guidance on technical and regulatory considerations for drug pro...

Medical Devices

Pull LASIK Off Market: Waxler

Former CDRH branch chief Morris Waxler tells CBS News LASIK eye surgery should be pulled from the market due to complications.

Human Drugs

Panel Nixes Lilly/Boehringer Diabetes Drug

FDAs Endocrinologic and Metabolic Drugs Advisory Committee votes to not recommend approval of Eli Lilly and Boehringer Ingelheims empagliflozin 2.5 mg...

Human Drugs

Botanical Safety Consortium Convened

FDA says the Botanical Safety Consortium has been formally convened under a memorandum of understanding between FDA and two research groups

Human Drugs

FDA Approves BeiGenes Brukinsa for Some Lymphomas

FDA approves BeiGenes Brukinsa capsules to treat some adults with mantle cell lymphoma.

Human Drugs

Isorx FDA-483 Released

FDA releases an FDA-483 with four inspection observations on an inspection at Isorx Corp.

Medical Devices

NantHealth Tumor Mutational Burden Assay Cleared

FDA clears a NantHealth 510(k) for its Omics Core, a whole exome tumor-normal in vitro diagnostic that measures overall tumor mutational burden in can...

Human Drugs

X4 Pharma Gains Breakthrough for Mavorixafor

FDA grants X4 Pharmaceuticals a breakthrough therapy designation for mavorixafor for the treatment of adult patients with WHIM (Warts, Hypogammaglobul...

Human Drugs

FDA Clinical Hold on Marker Leukemia Trial

FDA places a clinical hold on a Marker Therapeutics planned Phase 2 study of its MultiTAA T-cell therapy in post-allogeneic hematopoietic stem cell tr...